Trials / Completed
CompletedNCT00979953
Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee
A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 408 (actual)
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADL5859 | |
| DRUG | ADL5747 | |
| DRUG | Oxycodone CR | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-04-01
- Completion
- 2010-06-01
- First posted
- 2009-09-18
- Last updated
- 2015-08-14
- Results posted
- 2015-05-07
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00979953. Inclusion in this directory is not an endorsement.